1. Biophan Technologies, Inc. Company Overview and Update The Wall Street Analyst Forum – 16 th Annual Analyst Conference March 2, 2005 Michael Weiner, CEO

2. Biophan Technologies, Inc.(OTCBB: BIPH) Biophan’s Mission  Enable over $12 billion worth of medical devices shipping annually safe for use with MRI, and imageable. Many are not: Guidewires, catheters, endoscopes, biopsy needles Pacemakers, defibrillators, neurostimulators, drug pumps (safety issues, also imaging issues), pain control devices Stents, embolism clips, aneurysm clips, artificial hips, knees, most other orthopedics  Bring other innovations for competitive advantage to biomedical device and pharmaceutical companies.

3. Biophan Technologies, Inc.(OTCBB: BIPH) Summary Financial Information  Share Price (02.28.05): $1.55  52-Week High: $1.55  52 Week Low: $0.46  Shares Outstanding: 74 million  Float: 58 million  Market Cap: $114.7 million  Average Daily Volume: 510,454

4. BIOPHAN (OTC: BIPH)

5. Biophan Technologies, Inc.(OTCBB: BIPH) Biophan’s Solutions  MRI Safety: (many products contraindicated) RF filter from Johns Hopkins (heating) Biophan multi-filar wire solution (heating) “Anti-Antenna” lead design (induced voltages)  Image Compatibility  Nanomagnetic particle thin film coatings (Nanoset, LLC and Alfred University) Minimize image artifacts Makes catheters, guidewires, stents, and devices visible under MRI

6. Biophan Technologies, Inc.(OTCBB: BIPH) Management  Stu MacDonald, VP R&D at J&J division, with a 400 person organization  Jeff Helfer, VP Engineering – formerly Dir. Of Engineering at the same J&J division  John Lanzafame, President, Nanolution Division – former President STS Biopolymers, acquired by Angiotech (ANPI)  Robert Wood, VP Finance, Treasured and CFO, CPA in public and private firms  And now Dr. Michael Friebe, and Dr. Andreas Melzer, two well known leaders in MRI technologies

7. Biophan Technologies, Inc.(OTCBB: BIPH) Biophan-Europe  Acquired February, 2005, AMRIS (now Biophan Europe) adds enormous additional capability to Biophan  2 Ph.D. level MRI experts, Friebe and Gregor  MD, surgeon and inventor, Andreas Melzer, MD  Access to latest MRI devices  Excellent connections in the MRI community  Exciting, patented solutions

8. Biophan Technologies, Inc.(OTCBB: BIPH) Core Business  Offering our customers competitive advantage Through proprietary solutions that can gain marketshare for them FDA approval is pursued by the customer Marketing and distribution of the final device is theirs  We sell high margin components and develop annuities for our shareholders

9. Biophan Technologies, Inc.(OTCBB: BIPH) Relationship With Boston Scientific  Joint development agreement, originally entered into November, 2003  Recently moved to second and third phase, and has expanded to multiple products  One of the companies referred to in recent 10Q  Reached agreement on term sheet, working on final contract phase

10. MRI Device Imaging SE coronal image of 3 aluminum wires (1/32”). Wire (3) is uncoated. 123 Biophan’s thin-film nanomagnetic particle coating technology provides a controllable, “magnetic” signal capable of creating an image of the coated device. #3 is uncoated.

11. Biophan Technologies, Inc.(OTCBB: BIPH) Making Stents Imageable  Seeing blockage of stents has required an invasive procedure  Stents imageable under MRI would be competitively advantaged  Biophan’s business is competitive advantage for our customers through technology innovation  Nanoset has a coating solution  AMRIS, now Biophan-Europe, has a “retrofit” solution  Both solutions are PATENTED!  Together we “cover the waterfront”

12. Biophan Technologies, Inc.(OTCBB: BIPH) Implications  Impact the $5+ billion stent market  Help manufacturers make pacemakers, defibrillators, neurostimulators safe, and imageable – competitive advantage to our licensees  Make guidewires, catheters, endoscopes, biopsy needles safe and image compatible  Opens the field of interventional medicine under MRI (currently only X-Ray/Fluoroscopy)

13. Biophan Technologies, Inc.(OTCBB: BIPH) Biothermal Battery  Goal: To provide a long-lived electrical power system for implanted medical devices Powered by body heat differential.  Acquired 51% interest in TE-Bio, which holds an issued U.S. patent for the battery  Batteries are a $500 million market, sell for $100 to $225 each in the pacemaker, defibrillator and drug pump markets  Sold to same customers who need MRI safety

14. Biophan Technologies, Inc.(OTCBB: BIPH) Agreement with NASA  Announced on August 17 th a deal with NASA Ames Research Center for Nanotechnology to jointly develop the biothermal battery NASA wants technology for their long duration manned MARS mission for biosensing and miniature therapeutic devices Biophan gets commercial rights to jointly developed and NASA developed technology Nanotechnology and materials science advances makes the biothermal battery possible

15. Biophan Technologies, Inc.(OTCBB: BIPH) Substrate Polymer Coating Nanomagnetic layer Controlled Magnetic Field Drug bound to NMP carrier Controlled Magnetic Field A Controlled Magnetic Field B Particle type A Drug A Particle type B Drug B Surface Elution on Demand

16. Biophan Technologies, Inc.(OTCBB: BIPH) Reloading Drug Eluting Coatings Substrate Polymer Coating Concentration Gradient Controlled Magnetic Field Drug Molecules Drug bound to NMP carrier Nanomagnetic layer

17. Biophan Technologies, Inc.(OTCBB: BIPH) Guided Drug Delivery Solid tumor Apply magnetic field to concentrate particles Modulate field to release drug from particles Inject NMPs IV, NMP will circulate through the blood stream Other options for targeting: 1 - Direct injection into tumor site 2 - Coating NMP with antibodies to target tumor

18. Biophan Technologies, Inc.(OTCBB: BIPH) Other Solution Offerings  MRI Safe Drug Pump (non-magnetic)  Nanomagnetic particles for contrast agents Also used for  MRI compatibility  Reduce device heating  Enable DRUG DELIVERY CAPABILITIES!

19. NanoView tm MRI Contrast Agents NanoView tm Nano-particulate technology has the potential to provide a new consumable product capable of significantly enhancing MR detection sensitivity (i.e. lowest detectable concentration) and specificity (i.e. the ability to reliably detect the desired substance).

20. Biophan Technologies, Inc.(OTCBB: BIPH) PROTECTED, PROTECTED!  Technologies covered by 108 U.S. Patents  33 ISSUED  75 pending or allowed  Owned by Biophan or licensed exclusively to Biophan for the medical market  Plus many International patents

21. Biophan Technologies, Inc.(OTCBB: BIPH) Goals  Close major deal – underway, at contract phase  Close second deal – we have multiple prospects in the U.S. Europe, and Asia  List on major exchange – requires $5 million capital, we meet all other qualifications, we plan to file as soon as capital in hand

22. Biophan Technologies, Inc.(OTCBB: BIPH) Revenue Potential for MRI Safety and Visibility (by example, not a forecast) Customer Sales In Billion$ Year 3% (million$ yr) 5% (million$ yr) 13050 260100 390150 4120200 5150250 12360600

23. Biophan Technologies, Inc.(OTCBB: BIPH) Sensitivities  Deal Terms Improve with: Proof of principle Issued patents (the more the better) Multiple prospects Cash in the bank Capability Capacity

24. Biophan Technologies, Inc.(OTCBB: BIPH) Other Markets  Battery: $500 million  Contrast Agents: $800 million  Drug Pumps: $1 billion  Drug Delivery: $40 billion Cautions: Penetration can take time FDA approval and/or CE Mark could take time Bright side is, once deal is underway, patents and annuity streams can last a long time

25. Biophan Technologies, Inc.(OTCBB: BIPH) Biophan (OTC: BIPH) We don’t make medical devices; We make them safe, and imageable, for MRI And other competitive advantages for our customers Four of our six technologies are based on nanotechnology WWW.BIOPHAN.COM

26. Biophan Technologies, Inc.(OTCBB: BIPH) Thank You! More good things will unfold in 2005! BIO med PHA rma N ano Technologies